LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 1476 | 3536 | 3783 | 0.9346 | 0.9028 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 1476 | 3520 | 3734 | 0.9427 | 0.9137 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 1476 | 2636 | 3413 | 0.7723 | 0.6151 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 1476 | 3178 | 3783 | 0.8400 | 0.7589 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 1476 | 3154 | 3734 | 0.8447 | 0.7630 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 1476 | 2132 | 3413 | 0.6246 | 0.3550 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 1476 | 2902 | 3783 | 0.7670 | 0.6450 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 1476 | 2616 | 3734 | 0.7006 | 0.5331 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 1476 | 1978 | 3413 | 0.5795 | 0.2735 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 1476 | 2420 | 3783 | 0.6396 | 0.4390 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 1476 | 2261 | 3734 | 0.6055 | 0.3748 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1476 | 1869 | 3413 | 0.5476 | 0.2152 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1476 | 2074 | 3783 | 0.5482 | 0.2843 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1476 | 2136 | 3734 | 0.5720 | 0.3176 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 1476 | 1517 | 3413 | 0.4444 | 0.0225 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 1476 | 1747 | 3783 | 0.4617 | 0.1318 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 1476 | 1769 | 3734 | 0.4738 | 0.1445 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1476 | 3754 | 3788 | 0.9909 | 0.9865 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1476 | 3637 | 3731 | 0.9748 | 0.9621 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1476 | 4045 | 3796 | 1.0654 | 1.0952 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 1476 | 3782 | 3788 | 0.9983 | 0.9974 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 1476 | 3928 | 3731 | 1.0527 | 1.0784 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 1476 | 4096 | 3796 | 1.0788 | 1.1146 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 1476 | 4041 | 3788 | 1.0666 | 1.0972 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 2 | N16 | 72 | hr | 1476 | 4034 | 3731 | 1.0811 | 1.1202 |